Cargando…

Scientific Considerations for Evaluating Cancer Bioassays Conducted by the Ramazzini Institute

Background: The Ramazzini Institute (RI) has completed nearly 400 cancer bioassays on > 200 compounds. The European Food Safety Authority (EFSA) and others have suggested that study design and protocol differences between the RI and other laboratories by may contribute to controversy regarding ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Gift, Jeffrey S., Caldwell, Jane C., Jinot, Jennifer, Evans, Marina V., Cote, Ila, Vandenberg, John J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Institute of Environmental Health Sciences 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852791/
https://www.ncbi.nlm.nih.gov/pubmed/24045135
http://dx.doi.org/10.1289/ehp.1306661
_version_ 1782478726242500608
author Gift, Jeffrey S.
Caldwell, Jane C.
Jinot, Jennifer
Evans, Marina V.
Cote, Ila
Vandenberg, John J.
author_facet Gift, Jeffrey S.
Caldwell, Jane C.
Jinot, Jennifer
Evans, Marina V.
Cote, Ila
Vandenberg, John J.
author_sort Gift, Jeffrey S.
collection PubMed
description Background: The Ramazzini Institute (RI) has completed nearly 400 cancer bioassays on > 200 compounds. The European Food Safety Authority (EFSA) and others have suggested that study design and protocol differences between the RI and other laboratories by may contribute to controversy regarding cancer hazard findings, principally findings on lymphoma/leukemia diagnoses. Objective: We aimed to evaluate RI study design, protocol differences, and accuracy of tumor diagnoses for their impact on carcinogenic hazard characterization. Methods: We analyzed the findings from a recent Pathology Working Group (PWG) review of RI procedures and tumor diagnoses, evaluated consistency of RI and other laboratory findings for chemicals identified by the RI as positive for lymphoma/leukemia, and examined evidence for a number of other issues raised regarding RI bioassays. The RI cancer bioassay design and protocols were evaluated in the context of relevant risk assessment guidance from international authorities. Discussion: Although the PWG identified close agreement with RI diagnoses for most tumor types, it did not find close agreement for lymphoma/leukemia of the respiratory tract or for neoplasms of the inner ear and cranium. Here we discuss a) the implications of the PWG findings, particularly lymphoma diagnostic issues; b) differences between RI studies and those from other laboratories that are relevant to evaluating RI cancer bioassays; and c) future work that may help resolve some concerns. Conclusions: We concluded that a) issues related to respiratory tract infections have complicated diagnoses at that site (i.e., lymphoma/leukemia), as well as for neoplasms of the inner ear and cranium, and b) there is consistency and value in RI studies for identification of other chemical-related neoplasia. Citation: Gift JS, Caldwell JC, Jinot J, Evans MV, Cote I, Vandenberg JJ. 2013. Scientific considerations for evaluating cancer bioassays conducted by the Ramazzini Institute. Environ Health Perspect 121:1253–1263; http://dx.doi.org/10.1289/ehp.1306661
format Online
Article
Text
id pubmed-3852791
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher National Institute of Environmental Health Sciences
record_format MEDLINE/PubMed
spelling pubmed-38527912013-12-18 Scientific Considerations for Evaluating Cancer Bioassays Conducted by the Ramazzini Institute Gift, Jeffrey S. Caldwell, Jane C. Jinot, Jennifer Evans, Marina V. Cote, Ila Vandenberg, John J. Environ Health Perspect Review Background: The Ramazzini Institute (RI) has completed nearly 400 cancer bioassays on > 200 compounds. The European Food Safety Authority (EFSA) and others have suggested that study design and protocol differences between the RI and other laboratories by may contribute to controversy regarding cancer hazard findings, principally findings on lymphoma/leukemia diagnoses. Objective: We aimed to evaluate RI study design, protocol differences, and accuracy of tumor diagnoses for their impact on carcinogenic hazard characterization. Methods: We analyzed the findings from a recent Pathology Working Group (PWG) review of RI procedures and tumor diagnoses, evaluated consistency of RI and other laboratory findings for chemicals identified by the RI as positive for lymphoma/leukemia, and examined evidence for a number of other issues raised regarding RI bioassays. The RI cancer bioassay design and protocols were evaluated in the context of relevant risk assessment guidance from international authorities. Discussion: Although the PWG identified close agreement with RI diagnoses for most tumor types, it did not find close agreement for lymphoma/leukemia of the respiratory tract or for neoplasms of the inner ear and cranium. Here we discuss a) the implications of the PWG findings, particularly lymphoma diagnostic issues; b) differences between RI studies and those from other laboratories that are relevant to evaluating RI cancer bioassays; and c) future work that may help resolve some concerns. Conclusions: We concluded that a) issues related to respiratory tract infections have complicated diagnoses at that site (i.e., lymphoma/leukemia), as well as for neoplasms of the inner ear and cranium, and b) there is consistency and value in RI studies for identification of other chemical-related neoplasia. Citation: Gift JS, Caldwell JC, Jinot J, Evans MV, Cote I, Vandenberg JJ. 2013. Scientific considerations for evaluating cancer bioassays conducted by the Ramazzini Institute. Environ Health Perspect 121:1253–1263; http://dx.doi.org/10.1289/ehp.1306661 National Institute of Environmental Health Sciences 2013-09-17 2013 /pmc/articles/PMC3852791/ /pubmed/24045135 http://dx.doi.org/10.1289/ehp.1306661 Text en http://creativecommons.org/publicdomain/mark/1.0/ Publication of EHP lies in the public domain and is therefore without copyright. All text from EHP may be reprinted freely. Use of materials published in EHP should be acknowledged (for example, “Reproduced with permission from Environmental Health Perspectives”); pertinent reference information should be provided for the article from which the material was reproduced. Articles from EHP, especially the News section, may contain photographs or illustrations copyrighted by other commercial organizations or individuals that may not be used without obtaining prior approval from the holder of the copyright.
spellingShingle Review
Gift, Jeffrey S.
Caldwell, Jane C.
Jinot, Jennifer
Evans, Marina V.
Cote, Ila
Vandenberg, John J.
Scientific Considerations for Evaluating Cancer Bioassays Conducted by the Ramazzini Institute
title Scientific Considerations for Evaluating Cancer Bioassays Conducted by the Ramazzini Institute
title_full Scientific Considerations for Evaluating Cancer Bioassays Conducted by the Ramazzini Institute
title_fullStr Scientific Considerations for Evaluating Cancer Bioassays Conducted by the Ramazzini Institute
title_full_unstemmed Scientific Considerations for Evaluating Cancer Bioassays Conducted by the Ramazzini Institute
title_short Scientific Considerations for Evaluating Cancer Bioassays Conducted by the Ramazzini Institute
title_sort scientific considerations for evaluating cancer bioassays conducted by the ramazzini institute
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852791/
https://www.ncbi.nlm.nih.gov/pubmed/24045135
http://dx.doi.org/10.1289/ehp.1306661
work_keys_str_mv AT giftjeffreys scientificconsiderationsforevaluatingcancerbioassaysconductedbytheramazziniinstitute
AT caldwelljanec scientificconsiderationsforevaluatingcancerbioassaysconductedbytheramazziniinstitute
AT jinotjennifer scientificconsiderationsforevaluatingcancerbioassaysconductedbytheramazziniinstitute
AT evansmarinav scientificconsiderationsforevaluatingcancerbioassaysconductedbytheramazziniinstitute
AT coteila scientificconsiderationsforevaluatingcancerbioassaysconductedbytheramazziniinstitute
AT vandenbergjohnj scientificconsiderationsforevaluatingcancerbioassaysconductedbytheramazziniinstitute